Idera Pharmaceuticals to Present at Rodman & Renshaw 6th Annual Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its Toll-like Receptor-targeted drug discovery and development programs and a general corporate update at the Rodman & Renshaw 6th Annual Global Healthcare Conference on Monday, May 17, at 12:20 p.m. BST (7:20 a.m. EDT) being held at the Grosvenor House Hotel in London, UK.

The presentation will be available via live audio webcast on the Company’s website at www.iderapharma.com. Archived replays will also be located on the Company’s site following the events. The presentation date and time are subject to change. The most up-to-date information will be available on the Company’s website.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.

Idera Forward Looking Statements

This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the Company’s actual results to differ materially from those indicated by such forward-looking statements, including whether products based on the Company’s technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company’s products receive approval, they will be successfully distributed and marketed; whether the Company’s cash resources will be sufficient to fund the its operations; and such other important factors as are set forth under the caption "Risk Factors" in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2010, which important factors are incorporated herein by reference. The Company disclaims any intention or obligation to update any forward-looking statements.



CONTACT:

Idera Pharmaceuticals, Inc.
Kelly Luethje, 617-679-5519
[email protected]
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
[email protected]

KEYWORDS:   United Kingdom  United States  Europe  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Genetics  Infectious Diseases  Oncology  Pharmaceutical

MEDIA:

Logo
 Logo

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.